Gemseki Inc.
- Biotech or pharma, animal health
- Biotech or pharma, therapeutic R&D
- Investment bank
- Investor (buy-side or sell-side research)
- Other products or services
Gemseki helps biotech companies and academic institutions out-license their assets by facilitating global and regional licensing partnerships across therapeutic areas. We are a subsidiary of SNBL, a publicly traded Japanese company (Tokyo Stock Exchange: 2395:JP).
We have no retainer fee (100% contingent fee). Our success fee model is contingent entirely on achieving successful licensing transactions with pharma in Japan, China, South Korea, or globally.
For more information, visit: http://www.gemseki.com/en
)
)
){kind=logo}
){kind=logo}
){kind=logo}